Last reviewed · How we verify
Withdrawal of therapy
Withdrawal of therapy involves discontinuing an active pharmaceutical treatment to assess disease progression or allow natural resolution.
At a glance
| Generic name | Withdrawal of therapy |
|---|---|
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a clinical intervention rather than a drug itself, used in research or clinical practice to evaluate the natural history of a disease or the durability of treatment effect after cessation. It may be employed as a control arm in trials or as a therapeutic strategy to determine if continued medication is necessary.
Approved indications
Common side effects
Key clinical trials
- Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (PHASE2)
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation (PHASE2)
- Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer (PHASE2)
- Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder (PHASE2)
- TheraSphere With Durvalumab and Tremelimumab for HCC (PHASE2)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Withdrawal of therapy CI brief — competitive landscape report
- Withdrawal of therapy updates RSS · CI watch RSS
- Royal Brompton & Harefield NHS Foundation Trust portfolio CI